Repligen to Report Fourth Quarter and Full Year 2018 Financial Results
February 15 2019 - 7:30AM
Repligen Corporation (NASDAQ:RGEN) today announced that the Company
will report its fourth quarter and full year 2018 financial results
on Thursday, February 21, 2019. The Company will issue a press
release before the market opens and will host a conference call at
8:30 a.m. EST to discuss business updates and financial results for
the three- and twelve-month reporting periods ended December 31,
2018.
The conference call will be accessible by
dialing toll-free (866) 777-2509 for domestic callers and (412)
317-5413 for international callers. No passcode is required for the
live call. In addition, a webcast will be accessible via the
Investor Relations section of the Company’s website. Both the
conference call and webcast will be archived for a period of time
following the live event. The replay dial-in numbers are (877)
344-7529 for callers in the U.S., (855) 669-9658 for callers in
Canada and (412) 317-0088 for international callers. Replay
listeners must provide the passcode 10128740. About
Repligen CorporationRepligen Corporation (NASDAQ:RGEN) is
a global bioprocessing company that develops and commercializes
highly innovative products that deliver cost and process
efficiencies to biological drug manufacturers worldwide. Our
portfolio includes protein products (Protein A affinity ligands,
cell culture growth factors), chromatography products (OPUS®
pre-packed columns, chromatography resins, ELISA kits) and
filtration products (including XCell™ ATF, TangenX™ SIUS™ TFF and
Spectrum KrosFlo™ TFF filters and systems). The Protein A ligands
and growth factor products that we produce are essential components
of Protein A affinity resins used in biologics purification, and
cell culture media used to accelerate cell growth in a bioreactor.
Our innovative line of OPUS® chromatography columns, used in
bench-scale through commercial-scale biologics purification, are
delivered pre-packed to our customers with their choice of affinity
resin. Our XCell™ ATF Systems, available in stainless steel and
single-use configurations, are used in perfusion processes to
continuously concentrate cells and increase product yield from a
bioreactor. Single-use SIUS™ TFF cassettes and hardware are used
for biologic drug concentration in downstream filtration processes.
KrosFlo™ TFF cartridges and systems are used in both upstream and
downstream filtration processes. Repligen’s corporate headquarters
are in Waltham, MA (USA), with additional administrative and
manufacturing operations in Shrewsbury, MA, Rancho Dominguez, CA,
Lund, Sweden and Ravensburg, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Source: Repligen Corporation Sondra Newman Senior Director
Investor Relations(781) 419-1881 snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From May 2023 to May 2024